Latest news with #INN
Yahoo
6 days ago
- Business
- Yahoo
Surface Metals to Present at the Emerging Growth Conference on June 18th, 2025 and Enters into Marketing Contract
Vancouver, British Columbia--(Newsfile Corp. - June 16, 2025) - Surface Metals Inc. (CSE:SUR) (OTCQB: SURMF) (the "Company", or "Surface Metals") is pleased to announce that it has been invited to present at the Emerging Growth Conference on June 18th, 2025. Surface Metals invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. The Emerging Growth Conference is presenting on June 18th, 2025. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO, Steve Hanson, in real time. Surface Metals will be presenting at 1:45 PM Eastern time for 30 minutes. Please submit your questions in advance to questions@ or ask your questions during the event and Mr. Hanson will do his best to get through as many of them as possible. Please register to ensure that you are able to attend the conference and receive any updates that are released. See link below to register: If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on and on the Emerging Growth YouTube Channel, , and a link will be released after the event. All sessions will be conducted through video webcasts and will take place in the Eastern time zone. Additionally, Surface Metals has entered into an advertising and investor awareness campaign with Dig Media Inc. dba Investing News Network ("INN"). INN is a private company headquartered in Vancouver, Canada, dedicated to providing independent news and education to investors since 2007 at For the 12 month term of the agreement starting June 12th, INN will provide advertising on its website to increase awareness of Surface Metals for CAD$29,400. About Surface Metals Inc. Surface Metals Inc. is a mineral exploration company focused on acquiring, exploring, and developing battery and precious metal projects in partnership with leading technology and commodity companies in North America. Surface Metals holds a 90% interest in the Cimarron Gold Project in Nye County, Nevada, and through its US subsidiary, ACME Lithium US Inc., is advancing and developing a lithium brine resource at Clayton Lake Valley, Nevada and holds a sedimentary lithium claystone project at Fish Lake Valley, Nevada. Surface Metals Inc. has entered into a strategic exploration agreement with Snow Lake Resources Ltd, a leading partner, at a group of lithium projects in the pegmatite region of Shatford, Birse and Cat-Euclid Lakes in southeastern Manitoba. On behalf of the Board of Directors Steve HansonChief Executive Officer, President, and DirectorTelephone: (604) 564-9045info@ We Seek Safe Harbor To view the source version of this press release, please visit
Yahoo
06-06-2025
- Business
- Yahoo
JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website
- A refreshed global brand signals JCR's expanded international presence and unwavering focus on rare and genetic diseases worldwide - HYOGO, Japan, June 06, 2025--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the launch of its new global website. As the company turns 50, it is marking its growing footprint in Japan, the U.S., Europe, and Latin America with a unique website tailored for global audiences that reflects its passion for both science and humanity and brings the JCR brand to life for patients, physicians, and partners worldwide. "At JCR, we are committed to advancing science and delivering on the treatments for patients with unmet needs around the world," said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. "In September, we celebrate the 50th anniversary of the company I founded in 1975. The launch of our new global website reflects our evolution from an innovative startup in Japan to a global biopharmaceutical company. We remain dedicated to developing therapies for people with rare and genetic diseases and partnering with those who share our vision of transforming care for patients and families living with once untreatable diseases." The site features streamlined user interface and curated content for patients, physicians, partners, and investors – reinforcing JCR's commitment to bridge the gap between complex science and unmet needs of patients and families. For the past 50 years, JCR has built a reputation for the development of innovative new therapeutic approaches, including its more recent J-Brain Cargo® technology, a proprietary blood-brain barrier-penetrating technology that can deliver biotherapeutics into the central nervous system (CNS). This platform underpins several investigational pre-clinical and clinical staged therapies in JCR's pipeline, beginning with lysosomal storage disorders (LSDs), and it reflects the company's ongoing commitment to advancing treatments for CNS-related diseases across neurodegeneration, neuro-inflammation, and neuro-oncology conditions. JCR continues to strengthen its global research, development, and manufacturing capabilities, with a focus on addressing unmet medical needs and expanding therapeutic possibilities. Learn more about JCR, its technologies, and clinical development programs on its global website: About the J-Brain Cargo® Platform Technology JCR Pharmaceuticals has developed a proprietary blood-brain barrier-penetrating technology, J-Brain Cargo®, to bring biotherapeutics into the central nervous system. The first drug developed based on this technology and approved in Japan for the treatment a lysosomal storage disorder is IZCARGO® (INN: pabinafusp alfa). About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit the global website: View source version on Contacts Investors & Media:JCR Pharmaceuticals Co., Communicationsir-info@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
06-06-2025
- Business
- Business Wire
JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website
HYOGO, Japan--(BUSINESS WIRE)-- JCR Pharmaceuticals Co., Ltd. (TSE 4552; 'JCR'), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the launch of its new global website. As the company turns 50, it is marking its growing footprint in Japan, the U.S., Europe, and Latin America with a unique website tailored for global audiences that reflects its passion for both science and humanity and brings the JCR brand to life for patients, physicians, and partners worldwide. 'At JCR, we are committed to advancing science and delivering on the treatments for patients with unmet needs around the world,' said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. 'In September, we celebrate the 50 th anniversary of the company I founded in 1975. The launch of our new global website reflects our evolution from an innovative startup in Japan to a global biopharmaceutical company. We remain dedicated to developing therapies for people with rare and genetic diseases and partnering with those who share our vision of transforming care for patients and families living with once untreatable diseases.' The site features streamlined user interface and curated content for patients, physicians, partners, and investors – reinforcing JCR's commitment to bridge the gap between complex science and unmet needs of patients and families. For the past 50 years, JCR has built a reputation for the development of innovative new therapeutic approaches, including its more recent J-Brain Cargo ® technology, a proprietary blood-brain barrier-penetrating technology that can deliver biotherapeutics into the central nervous system (CNS). This platform underpins several investigational pre-clinical and clinical staged therapies in JCR's pipeline, beginning with lysosomal storage disorders (LSDs), and it reflects the company's ongoing commitment to advancing treatments for CNS-related diseases across neurodegeneration, neuro-inflammation, and neuro-oncology conditions. JCR continues to strengthen its global research, development, and manufacturing capabilities, with a focus on addressing unmet medical needs and expanding therapeutic possibilities. Learn more about JCR, its technologies, and clinical development programs on its global website: About the J-Brain Cargo ® Platform Technology JCR Pharmaceuticals has developed a proprietary blood-brain barrier-penetrating technology, J-Brain Cargo ®, to bring biotherapeutics into the central nervous system. The first drug developed based on this technology and approved in Japan for the treatment a lysosomal storage disorder is IZCARGO ® (INN: pabinafusp alfa). About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit the global website:
Skift
20-05-2025
- Business
- Skift
First Hospitality Opens Up Investment Arm to Outside Capital
Baird reported on investor meetings they held with Summit Hotels management. Their takeaways included that INN believes lodging fundamentals are stable, with a 5% drop in RevPAR for the same store portfolio in April. When you exclude the Easter shift and last year's eclipse, INN said normalized performance would have been flattish. They have seen softer demand in recent weeks with a shorter booking window, but have not seen incremental demand deterioration in April and so far in May. Corporate transient demand has held in reasonably well with no broad-based cancellations. Government demand is down 20% to 25%, and INN's portfolio has been the subject of cancellations from Canadian travelers in Boston, Scottsdale, and South Florida. They used the description stable to describe expenses and margins as well, which is good news. On the capital allocation front, INN management told investors they are committed to repurchasing shares under its newly authorized $50 million program. Baird said their sense is that the company is already an active repurchaser. First Hospitality has opened up its decades-old investment arm, First Investors, to outside capital and launched the First Investors GP Fund to deploy $400 million in hotel acquisitions. The GP Fund is expected to supply sponsor capital for investment in six to ten hotels over the next two to three years, targeting 150 to 350 key premium-branded or independent lifestyle hotels in growth markets. The GP Fund platform is led by First Hospitality CEO David Duncan. About 20% of the fund will be First Hospitality's own capital. The GP Fund platform is led by Duncan and governed by an ownership group under Executive Chairman Sam Schwartz and Founder and Chairman Emeritus Stephen Schwartz. The first AC Hotel by Marriott in Kansas will open its doors on July 16, 2025. The AC Hotel Wichita Downtown will be in the restored Brown/Broadway Plaza Building. The 118-room boutique property will offer European-inspired accommodations in Kansas, tapas-style dining, flexible meeting space, and one of the largest hotel fitness centers in the region. Greenwood Hospitality, a strategic partner of Hotel Equities, will manage the AC Hotel Wichita Downtown. The Commercial Observer reported that the first casualty of the Los Angeles City Council voting to raise the minimum wage for hospitality workers to $30 an hour is the Hilton Los Angeles Universal City Hotel's expansion plans. Sun Hill Properties manages the 495-room hotel, and they had already signed a room block agreement to reserve hundreds of rooms for the 2028 Summer Olympic and Paralympic Games. The future of the $250 million expansion that was expected for that is now in doubt. The expansion would have added 395 rooms. If this goes through, that minimum wage would be the highest in the United States. Unite Here's (typical) response was to call the industry participants 'chicken little,' saying this must end. IHG Hotels & Resorts, in collaboration with owner DM Miramar Beach Hotel LLC and management DHRUV Management, finalized the opening of a newly converted Holiday Inn Express & Suites hotel in Destin, FL. The Holiday Inn Express & Suites Destin - Miramar Beach offers 74 guest rooms, an outdoor pool, and a fitness center. It is located across from what is described as the nation's largest shopping outlet, Silver Sands Premium Outlets. The Kissimmee Place Development Group has proposed a 60,000-square-foot Hyatt Studios hotel with 3,000 square feet of conference space at the Florida city's airport. The hotel is one of two that the Cape Canaveral-based developer has proposed on city-owned land. The city is going to consider this proposal, which also includes the addition of a flight training campus for the rest of the property. Hard Rock International unveiled development plans for REVERB by Hard Rock Mazatlan, Mexico. Operadora Martres S.A. de C.V. is the project developer. The new build project is expected to open in June 2028 with 170 rooms with beachfront views. The Rosewood Mandarina in Nayarit, Mexico, opened, Rosewood's fourth property in Mexico. RLH Properties developed the resort and includes 134 ultra-luxury accommodations, including three specialty suites and two expansive standalone villas offering private plunge pools, expansive terraces, and bespoke design elements. The highlight of the rooms is the Canalan Beachfront Villas and the Cora Four Bedroom Mountaintop Villa, complete with infinity pools. Amenities include the Mandarina Golf Club, multiple dining venues that will continue to open through the year, four oceanfront pools, a fitness center, and the signature Asaya Spa. The Gold N Silver Inn in Reno, NV, will be undergoing significant renovations. Jacobs Entertainment owns the property and has pledged to preserve the inn with the renovations. The Inn's breakfast and lunch items will remain, but will be joined by new offerings. The Inn will close temporarily on June 1 with plans to reopen in time for New Year's Eve. The renovations are part of Jacobs Entertainment's broader investment in downtown Reno, with projects also being done on the J Resort and the J Resort's Reno Neon Line. Five parcels of land tied to the Reno Kimpton project were sold in a quiet auction at the Washoe County, NV courthouse steps. The trustee sale resulted in only one bidder, Court Street Ventures LLC, bidding $1 million. This is the LLC that triggered the foreclosure sale of the parcels over an $11.3 million loan to project developer CAI Reno Hotel Partners LLC, which went into default last year. Court Street Ventures is still locked in a legal battle with CAI over the Reno Kimpton project's bankruptcy, but Court Street said they plan to sell the property so they can recover as much as they can. CAI filed for Chapter 11 last year while continuing operations. Court Street wants it converted to a Chapter 7 to bring in a trustee to oversee and liquidate assets. A decision on the bankruptcy case will be made on June 2. CAI said they reached out to Court Street, offering a $2 million payment and payments of $1 million per month to delay the trustee sale until June 20th, but the offer was rejected. The 73-room Cobblestone Hotels & Suites has opened in Foley, Alabama. Eddie Spence of Gulf Shores is a partner with Cobblestone on the $10 million hotel development. This is the second Cobblestone hotel in Alabama. Cobblestone said they also plan to break ground on a 54-unit hotel off the two square in Bay Minette, with Spence also being a partner there. Personnel News Remington Hospitality announced the appointment of Ben Perelmuter as their new Chief Executive Officer effective June 2. Perelmuter joins Remington from TPG Hotels & Resorts where he was President and Chief Operating Officer. Perelmuter succeeds Dean Sloane who served as CEO for the past eight years. He announced in April he was leaving. Dreamscape Hospitality announced the appointment of Ryan Miyamoto as Vice President of Operations. He will oversee the operational performance of Dreamscape's portfolio. Miyamoto spent the past 18 years with Aimbridge Hospitality in various capacities, most recently as VP of Operations. Europe Highlights Hyatt Hotels has opened its first hotel in Croatia, the Hyatt Regency Zadar, located on the Adriatic Coast, close to Zadar's UNESCO-listed Old Town. Hyatt Regency Zadar features 133 guestrooms and suites, dining spaces, and over 7,965 square feet of event space.
Yahoo
10-05-2025
- Business
- Yahoo
Why ‘Rich Dad' Robert Kiyosaki Is Buying Silver Right Now — Should You Invest, Too?
Stock market turbulence might be bad for equity investors, but it's usually good for people who invest in precious metals such as silver and gold. Among the latter is financial author Robert Kiyosaki, who recently praised silver in a post on X. Read More: Find Out: In the post, dated April 22, Kiyosaki called silver the 'biggest investment bargain' today. 'Gold has already hit all time highs,' he wrote. 'I have plenty of Bitcoin. And silver is still 50% below its all time high … today about $35 [an ounce]. I believe silver will [increase] 2X to $70 this year.' That's a pretty bold prediction — and one many experts might find overly optimistic. Since Kiyosaki wrote those words, the price of silver has fallen below $35 an ounce. It would have to skyrocket in a hurry to reach $70. However, there are reasons silver might be a good investment right now. Like gold, silver is considered a safe haven when stocks are volatile because of the metal's inherent value and its application in different industries. Silver is also considered a hedge against economic uncertainty, and the world has seen plenty of that due to President Donald Trump's sweeping tariff plans. 'Precious metals, including silver, have benefited from the volatility created by the Trump administration's constant tariff threats since the beginning of the year,' the Investing News Network (INN) noted in an April blog. 'These threats have caused chaos throughout global equity and financial markets, prompting more investors to seek safe-haven assets to stabilize their portfolios.' Discover Next: The upshot is that silver prices have mostly been on the rise in 2025 despite occasional choppiness. Silver traded at $32.85 an ounce as of early Wednesday, May 7, according to data from Kitco. That's up from $28.90 at the close of 2024 — a gain of about 14%. That's a very strong gain when compared with the stock markets, which are down for the year despite recent momentum. But silver's price gain still lags behind that of gold, which could be why Kiyosaki calls silver a 'bargain.' As Barron's reported this week, market dynamics could be shifting in silver's favor. A recent Wall Street winning streak led some investors to sell gold because its price has risen so high. One advantage silver has over gold is that it has a 'wider range' of industrial uses, Barron's noted. This could help boost its price in the coming months, which means buying now would be a profitable move. But there is an important wild card to consider: the economy. One fear is that Trump's tariffs will create a global trade war that will ultimately lead to a recession. This, in turn, could cause a slowdown in global manufacturing, which would lower demand for silver's industrial uses and send its price south. So far, that hasn't happened. But things could change quickly if Trump's tariffs lead to a trade war. 'There is a lot of concern regarding industrial demand, as tariffs could cause demand destruction as costs go up,' Peter Krauth, editor of the Silver Stock Investor told the INN last month. This scenario could lead to lower silver prices a few months down the road. For now, though, silver continues to trend higher, and many experts suggest it is still a good time to buy. More From GOBankingRates 5 Types of Vehicles Retirees Should Stay Away From Buying How Far $750K Plus Social Security Goes in Retirement in Every US Region 4 Things You Should Do if You Want To Retire Early 12 SUVs With the Most Reliable Engines Sources: Robert Kiyosaki, X Nasdaq/Investing News Network, Silver Price Update: Q1 2025 in Review Barron's, Gold Prices Are Crushing Silver. Why That Could Change Soon Kitco, Live Charts Silver This article originally appeared on Why 'Rich Dad' Robert Kiyosaki Is Buying Silver Right Now — Should You Invest, Too? Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
